RE-BVS – Piemonte Repository

Sfoglia per AUTORE
FARIñAS-MADRID L
Collezione AO Ordine Mauriziano

Items : 3

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2.

2024
AO Ordine Mauriziano

Colombo N; Biagioli E; Harano K; Galli F; Hudson E; Antill Y; Choi CH; Rabaglio M; Marmé F; Marth C; Parma G; Fariñas-Madrid L; Nishio S; Allan K; Lee YC; Piovano E; Pardo B; Nakagawa S; McQueen J; Zamagni C; Manso L; Takehara K; Tasca G; Ferrero A; Tognon G; Lissoni AA; Petrella M; Laudani ME; Rulli E; et alii...

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. in Gynecologic oncology / Gynecol Oncol. 2024 Jun;185:202-211. doi: 10.1016/j.ygyno.2024.05.016. Epub 2024 Jun 3.

2024
AO Ordine Mauriziano

Makker V; Perez-Fidalgo JA; Valabrega G; Hamilton E; Van Gorp T; Sehouli J; Reginá?ová K; Richardson DL; Perri T; Oza AM; Miller DS; Alía EMG; De Giorgi U; Henry S; Spitz DL; Wimberger P; Bedna?íková M; Chon HS; Martínez-Garcia J; Pisano C; Berek JS; Romero I; Scambia G; Fariñas-Madrid L; Buscema J; Schochter F; Li K; Kalyanapu P; Walker CJ; et alii...

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5.

2023
AO Ordine Mauriziano

Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; et alii...